Form 4: Adicet Bio CSO Reports Tax Withholding Post-Split

Adicet Bio's Chief Scientific Officer, Blake Aftab, reported the disposition of 535 common shares for tax withholding purposes following a recent reverse stock split.

Summary

• Blake Aftab, Chief Scientific Officer of Adicet Bio, Inc. (ACET), reported a transaction on January 24, 2026.
• 535 shares of common stock were disposed of at a price of $8.44 per share.
• This disposition represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting of restricted stock units and does not constitute a sale by Mr. Aftab.
• Following this transaction, Mr. Aftab beneficially owns 2,981 shares of Adicet Bio common stock.
• The reported beneficial ownership reflects a 1-for-16 reverse stock split effected by Adicet Bio on December 30, 2025.

Sentiment

Score: 5

Explanation: The filing reports a routine tax withholding transaction for an executive, which is a neutral event. The mention of a reverse stock split could be perceived negatively, but the filing itself is purely factual about the transaction.

Positives

• The disposition of shares was for tax withholding purposes, not a voluntary sale by the officer, indicating continued holding of the remaining equity.

Negatives

• NA

Risks

• The beneficial ownership reflects a 1-for-16 reverse stock split effected by the Issuer on December 30, 2025, which can sometimes indicate challenges with stock price or market capitalization.

Future Outlook

NA

Industry Context

NA

Stakeholder Impact

• Shareholders: Provides transparency on insider ownership changes and the impact of the reverse stock split on holdings.
• Employees: Reflects standard compensation practices (RSU vesting and tax withholding).

Key Dates

Recommendation

This Form 4 details a routine tax withholding transaction by a company executive and confirms the impact of a prior reverse stock split. It does not provide new fundamental information to warrant a change in investment recommendation.

Keywords

Adicet Bio, ACET, Form 4, insider transaction, stock split, tax withholding, Blake Aftab, Chief Scientific Officer